Medtronic MDT Neuroscience — Reportable segment operating profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's neuroscience — reportable segment operating profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's neuroscience — reportable segment operating profit?
- Medtronic (MDT) reported neuroscience — reportable segment operating profit of $879M in Q1 2026.
- How has Medtronic's neuroscience — reportable segment operating profit changed year-over-year?
- Medtronic's neuroscience — reportable segment operating profit increased by 2.4% year-over-year, from $858M to $879M.
- What is the long-term trend for Medtronic's neuroscience — reportable segment operating profit?
- Over 4 years (2022 to 2026), Medtronic's neuroscience — reportable segment operating profit has grown at a -5.6% compound annual growth rate (CAGR), from $3.86B to $3.06B.
- What does neuroscience — reportable segment operating profit mean?
- The profit earned by the Neuroscience business unit from its core operations.
- How do you interpret neuroscience — reportable segment operating profit?
- An increase indicates improved operational efficiency or higher margins within the neuroscience product portfolio, while a decrease suggests rising costs or pricing pressure.
- How does neuroscience — reportable segment operating profit compare across companies?
- Comparable to segment-level operating income reported by diversified medical device peers like Abbott or Boston Scientific.